Psychedelic-assisted therapy for
cancer, PTSD, depression, and trauma.
Advancing Psychedelic Therapy Through Clinical Research
Expertise Informed by Experience
Sunstone is guided by a team of Clinical Research Coordinators with over 30 years of combined clinical expertise and over 5 years of specialized experience in psychedelic research.
We are currently offering trials to address depression, treatment-resistant depression, cancer and depression, and adjustment disorder. These trials use a variety of psychedelic compounds including, but not limited to psilocybin, MDMA, DMT and analogs.
Explore Open Studies- Adjustment Disorder (AD)
- Advanced Illness
- Generalized Anxiety Disorder
- Major Depressive Disorder (MDD)
- Major Depressive Disorder in Patients with Cancer
- Post-Traumatic Stress Disorder
- Postpartum Depression
- Treatment-Resistant Depression
- Psilocybin & Analogs
- MDMA & Analogs
- LSD & Analogs
- DMT & Analogs
- Methylone & Analogs
- atai Life Sciences
- Beckley Psytech
- Compass Pathways
- Cybin
- Resilient Pharmaceuticals
- Reunion Neuroscience
- Transcend Therapeutics
- Usona Institute
- Adventist HealthCare
- Dana-Farber Cancer Institute
- Johns Hopkins Center for Psychedelic &
Consciousness Research - McGill University
- Memorial Sloan Kettering Cancer Center
- The University of Vermont
Participating in a clinical trial at Sunstone contributes to advancing scientific knowledge in the field of mental health research. Sunstone’s clinical team has authored 13 papers on psychedelic research in leading journals, including Cancer, JAMA Oncology, and NIH-Heals.
View Published Research
Our Mission
Sunstone in the News
Researchers from Sunstone Therapies, Dana-Farber Cancer Institute, Harvard Medical School, and the University of Vermont have published new findings that deepen understanding of how psilocybin-assisted group therapy can help people with cancer and depression navigate profound existential challenges.
Fall 2025 At Sunstone Therapies, healing is understood as a journey—one that unfolds with time, trust, and compassionate care. Known […]
Blending Science, Story, and the Human Side of Healing October, 2025 — Sunstone Therapies CEO Dr. Manish Agrawal joined Dan […]
At Sunstone Therapies, we believe healing goes deeper than the surface. While traditional oncology focuses on physical treatments, many patients still struggle with the psychological and emotional challenges of cancer. Our mission is to address the whole patient, which is why we created the 2Dose Study. This clinical trial, led by Dr. Manish Agrawal, builds on our initial study where 80% of participants experienced a greater than 50% reduction in depressive symptoms. The 2Dose Study will explore whether psilocybin is more effective than an active placebo and if two doses are better than one. The trial is open to people with all stages of cancer, not just advanced disease.
A new paper published in Psychedelic Medicine introduces a novel model combining Meaning-Centered Psychotherapy (MCP) with psilocybin-assisted therapy (PAT) for patients with advanced cancer and depression. Developed from Sunstone Therapies’ investigator-initiated trial, the approach—called MCP-PSIL—aims to help patients reduce distress and find deeper meaning while navigating serious illness.
In psychedelic therapy clinical research, setting clear expectations is paramount. Transparent communication about potential disappointments can significantly reduce anxiety and foster a more grounded, trusting, and ultimately, healing journey for participants.
Co-founder and CEO, Dr. Manish Agrawal, recently shared his expertise and vision for the future of psychedelic-assisted therapy in oncology in a four-part interview series with Pharmacy Times’ Lead Editor, Alana Hippensteele.
Sunstone is pleased to begin enrollment of two clinical studies exploring the therapeutic potential of DMT (N,N-dimethyltryptamine) and its analogs.
June 16, 2025 | A new study conducted by Sunstone Therapies suggests that a single dose of psilocybin, combined with psychological support, can provide sustained relief from depression for some cancer patients.
Manish Agrawal, MD, Co-Founder and CEO of Sunstone Therapies Manish Agrawal, MD, brings an extensive academic, clinical, and research background […]